Zobrazeno 1 - 6
of 6
pro vyhledávání: '"James L Wilder"'
Autor:
Shahin Shajahan, Mansoor M. Ahmed, Joseph Pulliam, James L Wilder, John R. van Nagell, Eun Y. Lee, Frederick R. Ueland, R.Scott Rushing, Subodh M. Lele, Damodaran Chendil
Publikováno v:
Gynecologic Oncology. 91:9-14
Objective Several tumors express the protein product of the protooncogene c- KIT. Some of these respond to imatinib mesylate, a tyrosine kinase inhibitor. The tumors that respond frequently have mutation(s) in exon 11 of c- KIT that encodes for the r
Autor:
James L. Wilder
Publikováno v:
Drug Information Journal. 26:395-403
As pharmaceutical firms search for effective new ways to improve and reduce the time required to complete their paper-bound drug development process, a promising new technology known as imaging continues to be embraced with tremendous enthusiasm. Unf
Autor:
Michael L. Cibull, Edward J. Pavlik, James L Wilder, Warner K. Huh, J. Hunter, Paul D. DePriest, M. B. Reedy, L. Puls, Robert V. Higgins, J.R. van Nagell, Paola A. Gehrig, Richard J. Kryscio, Frederick R. Ueland, W. Merritt, Susan C. Modesitt, Brian M. Slomovitz, Kelly J. Manahan, David E. Cohn, J. Giesler, Charles S. Dietrich, M. Powell
Publikováno v:
Gynecologic oncology. 99(3)
Objective. To determine the efficacy of adjuvant platinum-based chemotherapy in Stage I uterine papillary serous carcinoma (UPSC). Methods. A retrospective multi-institutional investigation was performed to identify surgically staged patients with St
Autor:
James L Wilder, John R. van Nagell, Nada H. Khattar, Charlotte S. Kaetzel, Jianming Yin, Shahin Shajahan, Richard J. Kryscio, Rodney S Rushing, Dawn M Wilder, Subodh M. Lele, Rick Beaven, Frederick R. Ueland
Publikováno v:
Gynecologic oncology. 92(2)
Objective . Expression analysis of estrogen receptor-beta (ER-β) and estrogen receptor-alpha (ER-α) in tamoxifen-associated malignant endometrial tumors (TAMET) has not previously been published. Antiestrogens complexed with ER-β have been reporte
Autor:
Tyler O. Kirby, Ronald J. Whitley, Robert V. Higgins, Richard J. Kryscio, Edward J. Pavlik, John R. van Nagell, Paul D. DePriest, James L Wilder, Frederick R. Ueland, John Michael Straughn
Publikováno v:
Gynecologic oncology. 89(2)
The goal of this study was to determine the clinical implications of a progressively rising serum CA-125 level in the normal (35 U/ml) range in ovarian cancer patients with complete response to therapy.A multi-institutional investigation was undertak
Publikováno v:
Gynecologic Oncology. 110:268-269